These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9591278)

  • 1. Public sector funding in the UK.
    Owen DA
    Nat Biotechnol; 1998 May; 16 Suppl():64. PubMed ID: 9591278
    [No Abstract]   [Full Text] [Related]  

  • 2. Antisoma-Roche deal--a new kind of buyout?
    Mitchell P
    Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
    [No Abstract]   [Full Text] [Related]  

  • 3. Exposing drug industry funding of UK patient organisations.
    Ozieranski P; Rickard E; Mulinari S
    BMJ; 2019 May; 365():l1806. PubMed ID: 31122928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competitive collaboration in the pharmaceutical and biotechnology industry.
    Bingham A; Ekins S
    Drug Discov Today; 2009 Dec; 14(23-24):1079-81. PubMed ID: 19835979
    [No Abstract]   [Full Text] [Related]  

  • 5. The funding market for nursing research.
    Salter B
    J Adv Nurs; 1985 Mar; 10(2):155-63. PubMed ID: 3845941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New IGF drug stirs competition in growth factor segment.
    Ratner M
    Nat Biotechnol; 2005 Oct; 23(10):1192. PubMed ID: 16211044
    [No Abstract]   [Full Text] [Related]  

  • 7. UK drug companies must disclose funding of patients' groups.
    Day M
    BMJ; 2006 Jan; 332(7533):69. PubMed ID: 16410564
    [No Abstract]   [Full Text] [Related]  

  • 8. 2Q10-spreading the wealth.
    Yang W
    Nat Biotechnol; 2010 Aug; 28(8):771. PubMed ID: 20697393
    [No Abstract]   [Full Text] [Related]  

  • 9. UK firms buy into drug design skills of US start-ups.
    Nature; 1995 Feb; 373(6513):372. PubMed ID: 7830777
    [No Abstract]   [Full Text] [Related]  

  • 10. Celltech announces public offering.
    Ward M
    Nature; 1993 Nov; 366(6450):9. PubMed ID: 8232544
    [No Abstract]   [Full Text] [Related]  

  • 11. Deconstructing Myogen's market cap.
    Ransom J
    Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
    [No Abstract]   [Full Text] [Related]  

  • 12. How do you measure "success" in a biotechnology company?
    Greetham EM
    Nat Biotechnol; 1998 May; 16 Suppl():59-60. PubMed ID: 9591275
    [No Abstract]   [Full Text] [Related]  

  • 13. What mergers can do for you.
    Acharya A
    Nat Biotechnol; 2011 Jun; 29(6):477-9. PubMed ID: 21796820
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotech's wonder ride.
    Rynecki D
    Fortune; 2000 Mar; 141(5):435-6. PubMed ID: 10788046
    [No Abstract]   [Full Text] [Related]  

  • 15. Biotech's billion dollar breakthrough.
    Stipp D
    Fortune; 2003 May; 147(10):96-8, 100, 103. PubMed ID: 12776500
    [No Abstract]   [Full Text] [Related]  

  • 16. This Dutchman is flying.
    Watson N
    Fortune; 2003 Jun; 147(13):89-90. PubMed ID: 12827720
    [No Abstract]   [Full Text] [Related]  

  • 17. Profiles of four top biotech companies in India.
    Suresh N; Rao ChS
    Biotechnol J; 2009 Mar; 4(3):295-300. PubMed ID: 19296435
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 19. Where have all the investors gone?: the case for consolidation.
    Esposito RS; Ostro MJ
    Nat Biotechnol; 1998 May; 16 Suppl():63. PubMed ID: 9591277
    [No Abstract]   [Full Text] [Related]  

  • 20. Genzyme and Isis strike megadeal.
    Mack GS
    Nat Biotechnol; 2008 Mar; 26(3):251-3. PubMed ID: 18327216
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.